COVID-19 therapeutics
Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …
has been studied and deployed. Healthcare providers have multiple treatment approaches …
Digital and precision clinical trials: Innovations for testing mental health medications, devices, and psychosocial treatments
Mental health treatment advances-including neuropsychiatric medications and devices,
psychotherapies, and cognitive treatments-lag behind other fields of clinical medicine such …
psychotherapies, and cognitive treatments-lag behind other fields of clinical medicine such …
[HTML][HTML] Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a …
Background Repurposed drugs with host-directed antiviral and immunomodulatory
properties have shown promise in the treatment of COVID-19, but few trials have studied …
properties have shown promise in the treatment of COVID-19, but few trials have studied …
The IRE1α-XBP1 arm of the unfolded protein response is a host factor activated in SARS-CoV-2 infection
SARS-CoV-2 infection can cause severe pneumonia, wherein exacerbated inflammation
plays a major role. This is reminiscent of the process commonly termed cytokine storm, a …
plays a major role. This is reminiscent of the process commonly termed cytokine storm, a …
[PDF][PDF] Molecular docking as a tool for the discovery of novel insight about the role of acid sphingomyelinase inhibitors in SARS-CoV-2 infectivity
Abstract Recently, COVID-19, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) and its variants, caused> 6 million deaths. Symptoms included respiratory …
(SARS-CoV-2) and its variants, caused> 6 million deaths. Symptoms included respiratory …
[HTML][HTML] Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19
Background Post-acute sequelae of COVID-19 (PASC) produce significant morbidity,
prompting evaluation of interventions that might lower risk. Selective serotonin reuptake …
prompting evaluation of interventions that might lower risk. Selective serotonin reuptake …
Antidepressant-induced membrane trafficking regulates blood-brain barrier permeability
As the most prescribed psychotropic drugs in current medical practice, antidepressant drugs
(ADs) of the selective serotonin reuptake inhibitor (SSRI) class represent prime candidates …
(ADs) of the selective serotonin reuptake inhibitor (SSRI) class represent prime candidates …
A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID …
MI Prasanth, DL Wannigama, AM Reiersen… - Scientific Reports, 2024 - nature.com
Abstract There have been 774,075,242 cases of COVID-19 and 7,012,986 deaths worldwide
as of January 2024. In the early stages of the pandemic, there was an urgent need to reduce …
as of January 2024. In the early stages of the pandemic, there was an urgent need to reduce …
Navigating the complexities of drug development for inflammatory bowel disease
Inflammatory bowel disease (IBD)—consisting of ulcerative colitis and Crohn's disease—is a
complex, heterogeneous, immune-mediated inflammatory condition with a multifactorial …
complex, heterogeneous, immune-mediated inflammatory condition with a multifactorial …
Exploring the causal effects of depression and antidepressants on COVID-19
L Fu, A Baranova, H Cao, F Zhang - Journal of Affective Disorders, 2024 - Elsevier
Background While existing studies have suggested an increased risk of COVID-19 in
patients with depression, the causal impact of MDD on the severity of COVID-19 remains to …
patients with depression, the causal impact of MDD on the severity of COVID-19 remains to …